BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use INDICATIONS AND USAGE BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation ...

BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%, for topical ophthalmic use INDICATIONS AND USAGE BYQLOVI is a corticosteroid indicated for the treatment of post-operative inflammation ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby ...

TAIPEI, May 7, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ('Formosa', 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc.

TAIPEI, May 6, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Apotex Inc ...

Clobetasol propionate ophthalmic suspension, 0.05% (APP13007), approved by the U.S. Food and Drug Administration (FDA) in March, 2024, was launched in the United States in September.

Clobetasol propionate ophthalmic suspension, 0.05% (APP13007), approved by the U.S. Food and Drug Administration (FDA) in March, 2024, was launched in the United States in September.